At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Triferic +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized 3 Period Crossover Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
In Brief
A Phase 2 clinical trial evaluating Triferic and Heparin for End Stage Renal Disease. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This study will investigate the effect of co-administration of Triferic and heparin on the ability to maintain circuit anti-coagulation and iron delivery when compared to control conditions when each treatment is administered via separate routes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartSep 2019
Primary CompletionJan 2020
TodayJul 2026
First PostedAug 1, 2019
Enrollment StartSep 30, 2019
Primary CompletionJan 16, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.9 years ago
Interventions
Trifericdrug
Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
Heparindrug
Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.